+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

KOL Perspectives: Rituximab Use in Lupus

  • ID: 4701802
  • Drug Pipelines
  • July 2018
  • Region: Global
  • 37 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

Summary

This KOL Insight briefing focuses on KOLs views of Rituximab Use in Lupus.

Questions topics -
  • Current & future use of RTX in lupus
  • Views on RTX’s Phase II/III EXPLORER trial re-analysis
  • Opinion on data demonstrating that RTX is effective for the management of refractory SLE
  • Views on data from the Phase II SYNBIoSe study assessing RTX + BEL combination therapy
  • Lupus patients most suitable for RTX + BEL combination therapy
  • Use of RTX + BEL combination therapy
Key Highlights
  • Most US KOLs stated that future launch of biosimilar RTX will have no impact on their overall use of RTX, but uptake will depend on price
  • Most KOLs highlighted that the level of background medication used in the EXPLORER trial was too high and consequently impeded results
  • Most KOLs flagged that payers may be a barrier to combination therapy use, especially given the lack of approval for RTX in lupus.
Scope
  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our Lupus key opinion leaders (KOLs).
In total, we conducted interviews with 10 KOLs -
  • 5 Europe-based & 5 N. America-based
  • Interviews performed during Q2 2018
KOL data is analyzed to produce -
  • Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts
Reasons to Buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on Rituximab Use in Lupus
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Executive Summary
  • Background
  • Research Panel Composition
  • Results & Implications
  • Appendix
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Roche
  • GSK
Note: Product cover images may vary from those shown
Adroll
adroll